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Raphael WittenbergAbstract
The ageing of the population across developed countries and beyond has increased the importance of examining
multi-morbidity. The recent paper by Arbelle et al. [Isr J of Health Policy Res. 2014;3:29] on multiple chronic conditions
in Israel’s Maccabi Health Care System (MHC) is a welcome and interesting contribution to the literature on this topic.
They found that the prevalence of multiple chronic conditions among the MHC population rises with age, is lower for
higher socioeconomic groups, and is higher than in a primary care population in Scotland studied by Barnett et al.
[Lancet. 2012;380:37–43].
The difference in prevalence between the two studies is unlikely to reflect entirely, or probably even mainly, real
differences in morbidity rates between the two countries. Systematic reviews have highlighted large differences in the
prevalence of multi-morbidity in different studies. Although the Israeli and Scottish study used similar definitions and
methods, the nature of the source data differed. It seems likely that the incentives to record the full range of patients’
conditions may differ between data sources depending on the uses of the data, which may in turn depend on the
country’s health care financing system. If this is correct, it will complicate comparisons between different jurisdictions.
It is important to consider not only the prevalence of multi-morbidity but also its costs to the health system and to wider
society. Cost of illness studies can be helpful in informing decisions about prioritisation of resources. Multi-morbidity
complicates such studies. The overall costs of health and social care for people with a specific condition would include
costs relating to any comorbidities. To examine the marginal impact on overall costs of each condition among those
with multiple conditions is likely to be complex and arguably not especially useful.Main text
The ageing of the population across developed countries
and beyond has increased the importance of examining
multi-morbidity. The recent paper by Arbelle et al. [1] on
multiple chronic conditions in Israel’s Maccabi Health
Care System (MHC) is a welcome and interesting contri-
bution to the literature on this topic. The authors show
that the prevalence of two or more chronic conditions
among the two million members of the Maccabi Health-
care Service is 38% and that it rises sharply with age
reaching over 90% after age 75 years.
The high prevalence of multi-morbidity clearly pre-
sents challenges for health care systems. As patients live
longer lives, they are at rising risk of developing multiple
chronic disorders. The management of combinations
of disorders is likely to be more complex than theCorrespondence: r.wittenberg@lse.ac.uk
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unless otherwise stated.management of single conditions. Arbelle et al. conclude
that ‘to effectively deal with multiple chronic conditions
health care systems must devise strategies, including but
not limited to, information technologies that enable shared
teamwork based on clinical guidelines which address the
problem of multiple, as opposed to single chronic disorders
in patients’ [1].
The authors used a similar methodology to that used
in a recent Scottish study of multi-morbidity by Barnett
et al. [2]. They found that the prevalence of multiple
chronic conditions among the MHC population is Israel
is statistically significantly higher than the prevalence in
the Scottish study population. The prevalence in the
Scottish population of two or more chronic conditions was
23.2% as against 38.1% in the MHC population. This is des-
pite differences in the age profile of the two populations:
Scotland has a higher proportion of older people and lower
proportion of children and young people than Israel.
The difference in prevalence between the two studies is
unlikely to reflect entirely, or probably even mainly, realhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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A systematic review of the literature by Marengoni et al.
[3] found that the prevalence of multi-morbidity, defined
as prevalence of two or more concurrent diseases, varied
widely between studies, in the case of older people from
55% to 98%. Fortin et al. [4] also found in their systematic
review of prevalence studies of multi-morbidity marked
variation in prevalence rates between different studies
especially at age 75, where prevalence in the general popu-
lation varied between 13.1% and 71.8%. The studies used
different definitions of multi-morbidity and different
recruitment methods. Fortin et al. recommend that ‘inves-
tigators should carefully consider the specific diagnoses
included and their number, as well as the operational
definition of multimorbidity’ [4].
Arbelle et al. [1] did use the same definition and gen-
eral approach as Barnett et al. [2]. What differed, apart
from the country in which the study was conducted, is
the nature of the source of the data. While the Israeli
study used data from an agency which acts as insurer,
care manager and care provider, the Scottish study used
data from primary care records. The Israeli MHC data
on chronic conditions is used as an input to care man-
agement and can be accessed by all physicians working
within the MHC plan. The Scottish data derive from the
records of the general practices with which the patients
are registered.
It is possible that use of different types of data sources
yields different prevalence rates of multiple chronic condi-
tions. It seems likely in particular that the incentives to rec-
ord the full range of patients’ conditions may differ between
data sources depending on whether the data source is used
for any finance purposes. Where it is used for financial pur-
poses, much may depend on the nature of the country’s
health care financing system. If this is correct, it will com-
plicate comparisons between different jurisdictions.
The choice of the appropriate method and data source
for estimating the prevalence of multiple chronic condi-
tions should take account of the purposes for which the
prevalence estimates are to be used. This raises various
questions about the underlying objective of estimating the
prevalence of multi-morbidity. It is important to be clear
which types of decisions on policy and practice such
information is intended to inform. It may be important
to estimate not just the prevalence of multi-morbidity
in general but to identify common combinations of condi-
tions where the specific combination of conditions requires
differences in treatment from the individual conditions. It
may also be important to understand not just the overall
prevalence of multi-morbidity but also how prevalence
varies by age, gender, socioeconomic group and other
population characteristics.
Arbelle et al. [1] found that the prevalence of multiple
chronic conditions rises sharply with age. This meansthat unless there is a significant compression of morbid-
ity demand for long term care will rise over the coming
decades as the population ages. As the authors stress,
there will be ‘an increasing need for tertiary as well as
secondary and primary prevention to prevent poor out-
comes of combinations of chronic disorders’ [1]. This
indicates the importance of developing effective ways to
prevent chronic conditions which tend to be associated
with other conditions in combinations which may be
complex and costly to manage.
The steep age gradient also means that unless there is
as high a quality of health and social care for people
with multiple chronic conditions as for people with a
single condition there is a risk that people in late old age
will receive lower quality care than younger people who
are less likely to have multiple conditions. Age differences
in quality of care, and access to some forms of care, can
be a cause for concern.
The study by Arbelle et al. found that, except for chil-
dren and adolescents, the prevalence of multiple chronic
conditions is higher among lower socioeconomic groups.
Marengoni et al. [3] found in their systematic review of
the literature that factors associated with multi-morbidity
include low socioeconomic status as well as older age and
female gender. Charlton et al. [5] specifically investigated
the impact of deprivation on the occurrence, outcomes
and health care costs of people with multiple morbidity in
England. They found that the higher incidence of disease,
associated with deprivation, channels deprived popula-
tions into categories of multiple morbidity with a greater
prevalence of depression, higher mortality and higher
costs. They conclude that this has implications for the way
resources are allocated between areas in England’s NHS.
More generally improved care for people with multiple
chronic conditions seems important in the context of
reducing health inequalities.
It is important to consider not only the prevalence of
multi-morbidity but also its costs to the health system
and to wider society. Lehnert et al. [6] conducted a sys-
tematic review of literature on health care utilisation and
costs of older people with multiple chronic conditions.
Studies they reviewed found that elders with more chronic
conditions had consistently more physician visits, experi-
enced more hospital stays and inpatient bed days, and
consumed more pharmaceuticals. Several of the studies
they reviewed showed a ‘curvilinear, nearly exponential
relationship’ in which costs roughly doubled for each
additional chronic condition. This finding suggests that
the costs associated with individual conditions cannot
simply be summed to produce an estimate of the costs
of combinations of conditions. They comment that ‘little
is known about the natural clustering of diseases, little
more about the prevalence of specific disease combina-
tions’ and recommend that future studies investigating
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Austerity following the recent financial crisis has in-
creased the importance of ensuring maximum health gain
from limited resources. This has increased the value of
cost of illness studies, which examine the economic im-
pact of specific health conditions on the public finances,
the health and care system and society more widely.
The relative costs of different health conditions is one
of the factors that should be taken into account in
considering priorities for service development and for
research. Such studies tend to examine the full costs of
health and social care for people with the condition under
consideration. To examine the marginal costs due to one
condition when people have with several conditions would
be complex and probably liable to a considerable degree
of uncertainty. Prince et al. [7] in their recent work on the
costs of dementia in the United Kingdom (UK), for
example, estimated the costs of all health and social care
for people with dementia and not just the costs of that
part of their care that relates to dementia.
People with dementia frequently have comorbidities,
for example the proportion of people with dementia
who also have diabetes is higher than the proportion of
people of the same age without dementia who have
diabetes. To try to split the costs of care for people with
dementia between costs of care for dementia, costs of
care for diabetes and costs of care for other comorbidi-
ties would be complex. It is also questionable whether it
would be useful. It is important to recognise however
that the sum of the costs of health and social care
summed across studies of the costs of different condi-
tions involve double-counting of some services and that
if a specific health condition could be prevented only
part of the costs estimated for it in cost of illness studies
would be saved.
There have been calls for improved care for people with
multiple chronic conditions. Tinetti et al. [8] point out
that ‘the most common chronic condition experienced by
adults is multimorbidity’ and argue that to ensure safe and
effective care for adults with multiple chronic conditions
‘health care must shift its current focus on managing
innumerable individual diseases’ to a focus on managing
multiple conditions. Vogeli et al. [9] conclude that ‘under-
standing how to care effectively for persons with multiple
chronic conditions is among the most important chal-
lenges our health care system faces’. Arbelle et al. [1]
stress the need for clinical guidelines to be improved and
adapted to account for patients with multiple chronic
conditions.
There have also been calls for more research into mul-
tiple chronic conditions. Tinetti et al. [6], for example,
comment that research funding organisations and indus-
try must ensure that research generates evidence thataccurately informs decision making for patients with
multiple chronic conditions. In a welcome recent develop-
ment the English National Institute for Health Research
(NIHR) has recently issued a call for applications for
research into the evaluation of interventions or services
delivered for older people with multimorbidity [10].
Commentary on Arbelle J E, Chodick G, Goldstein A
and Porath P (2014) Multiple chronic disorders - health
care system’s modern challenge in the Maccabi Health
Care System, Israel Journal of Health Policy Research.
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